Biotech: Page 2

Dive Awards

Vaccine Developers of the Year: BioNTech and Moderna

Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible.

By Ned Pagliarulo • Dec. 09, 2020

Dive Awards

Biotech of the Year: Seagen

A billion-dollar deal with Merck followed quick approvals for the company's second and third drugs, pushing Seagen's market value to over $30 billion.

By Ben Fidler • Dec. 09, 2020

Explore the Trendline➔

Trendline

Inside the global race for a coronavirus vaccine

Some 29 vaccine candidates are now in clinical studies. Early results from five leading efforts are encouraging, suggesting researchers are on the right track despite rapid acceleration of testing.

By BioPharma Dive staff

Dive Awards

The BioPharma Dive Awards for 2020

Vaccine developers and COVID-19 researchers took center stage in a year turned upside down by the pandemic.

By BioPharma Dive Team • Dec. 09, 2020

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Two cell therapies might soon be approved for the blood cancer. But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind.

By Jonathan Gardner , Ben Fidler • Dec. 08, 2020

Sarepta shares first results on next-generation Duchenne drug

The biotech claims early results from a Phase 2 study suggest one of its newer therapies may be more powerful at a lower dose than Exondys 51.

By Kristin Jensen • Dec. 08, 2020

UniQure offers a closer look at the leading hemophilia B gene therapy

Doctors on Tuesday got a more detailed idea of how the therapy works and who might be eligible to take it, as late-stage results were presented at ASH.

By Jacob Bell • Dec. 08, 2020

Lilly to pit Loxo cancer drug against top-selling rival after strong study results

Following positive data at ASH, Lilly will test a drug it acquired in last year's buyout of Loxo Oncology against Imbruvica, one of the world's best-selling cancer treatments.

By Ned Pagliarulo • Dec. 07, 2020

A CRISPR gene editing treatment continues to show promise for two blood diseases

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data.

By Ben Fidler • Dec. 05, 2020

4 storylines to track at the year's biggest meeting on blood diseases

A closely watched gene editing therapy, a slate of new multiple myeloma drugs and much more are set to highlight the American Society of Hematology conference this weekend.

By Ben Fidler , Ned Pagliarulo , Jacob Bell • Dec. 03, 2020

Ovid's plan to prove a shelved sleeping pill for a rare disease ends in disappointment

A quest by former Teva and Bristol Myers executive Jeremy Levin to develop an old drug for Angelman's syndrome fell short in a late-stage clinical trial.

By Ben Fidler • Dec. 02, 2020

With anemia data, Agios blood disease drug takes a crucial step forward

Phase 3 results announced Tuesday boost chances that Agios' drug might not just win approval for a rare type of anemia, but also be useful in treating other blood diseases.

By Ben Fidler • Dec. 01, 2020

Moderna, finishing key study, to ask FDA for emergency approval of coronavirus vaccine

New results confirm the shot's strong efficacy against COVID-19 and should raise confidence vaccination can prevent against severe symptoms as well. 

By Ben Fidler • Nov. 30, 2020

Biogen stocks up on Sage's brain drugs in $3B deal

Biogen and Sage each face challenges. While executives from both companies said the deal could provide a boost, investors don't appear to be sold just yet.

By Jacob Bell • UPDATED: Nov. 30, 2020 at 11:13 a.m.

Alnylam wins US approval for its third rare disease drug

The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price.

By Kristin Jensen • Nov. 24, 2020

Deep Dive

How Gilead finally spent its money

This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.

By Jacob Bell • Nov. 24, 2020

Amgen cuts Cytokinetics loose after heart drug disappointment

The smaller biotech vowed to push forward, although the pill's inability to prevent heart failure death may complicate its plans to win approval. 

By Jonathan Gardner • Nov. 23, 2020

Regeneron COVID-19 drug, used to treat Trump, cleared for emergency use

The drug is the second antibody-based treatment to win FDA emergency authorization this month, though supplies of both are very limited.

By Ben Fidler • Nov. 22, 2020

Stem cell therapy for ALS fails a large clinical trial

The therapy's developer, Brainstorm Therapeutics, blamed the setback on better-than-expected results from placebo-treated patients. The biotech still sees a path forward, however.

By Jacob Bell • Nov. 17, 2020

Moderna says vaccine prevents COVID-19 in large study, adding to hopes for several protective shots

Multiple effective vaccines will likely be needed to end the pandemic. Moderna's study results, which are equally strong as those reported by Pfizer and BioNTech last week, make that outcome more likely.

By Ben Fidler • Nov. 16, 2020

Intellia, beginning treatment in CRISPR study, secures Gates Foundation backing

The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology. 

By Kristin Jensen • Nov. 11, 2020

Pfizer invests in Homology, adding to gene therapy ambitions

Along with an equity stake, Pfizer will get right of first refusal on any deal involving Homology's most advanced therapies, which the biotech is developing for a rare metabolic disorder.

By Kristin Jensen • Nov. 10, 2020

Amgen's asthma drug delivers a needed win

A late-stage study found Amgen's tezepelumab benefited a variety of patients with severe asthma, results that one analyst called a "best-case outcome."

By Jacob Bell • Nov. 10, 2020

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

The regulator approved Lilly's synthetic antibody treatment for emergency use, but short supplies and logistical challenges could limit its initial impact.

By Ben Fidler • Nov. 09, 2020

5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug

The expert panel's decidedly negative vote on aducanumab raised questions about the drug's future, as well as the credibility of the FDA.

By Jacob Bell , Ned Pagliarulo , Ben Fidler • Nov. 09, 2020

FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt

In a tense meeting, a group of experts found Biogen and the FDA's case for aducanumab unpersuasive, voting overwhelmingly against the drug.

By Jacob Bell , Jonathan Gardner , Ned Pagliarulo • UPDATED: Nov. 7, 2020 at 7:15 p.m.